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Abstract 
Nanoparticle conjugation is a powerful method to reduce the side effects of anticancer 
agents such as doxorubicin by altering the pharmacokinetic profile of the drug. 
Nanoparticles can prolong circulation time and could also promote enhanced accumulation 
in tumors, either passively via the EPR effect or actively when decorated with targeting 
motifs. For the particular case of doxorubicin, hydrazone-based conjugation chemistry is 
popular, but commonly involves laborious chemical transformation steps1. Here we report 
on a straightforward route for the synthesis of hydrazine-based doxorubicin-polymer 
conjugates starting from a polymeric activated ester scaffold onto which doxorubicin-
reactive hydrazide moieties are introduced by simple treatment with hydrazine. Using block 
copolymers composed of hydrophobic reactive ester block we demonstrate a simple route 
to assemble core-crosslinked doxorubicin-loaded nanoparticles. The latter largely retain 
their bioactivity in vitro. In a zebrafish embryo ´ pre-murine´ in vivo model we demonstrate 
a dramatic reduction in systemic toxicity of doxorubicin upon nanoparticle-conjugation and 
also demonstrate enhanced tumor accumulation and tumor growth reduction.  
 
 
 
 
INTRODUCTION 
Doxorubicin is amongst the most widely used anticancer agents2,3. Like other 
anthracyclines, it mainly acts through intercalation with the cancer cell DNA, leading to 
disruption of transcription and replication processes, resulting in cell death4,5. However, 
like most chemotherapeutics, doxorubicin suffers from reduced therapeutic efficiency due 
to occurrence of harmful side effects6. These include nausea, hair loss, bone marrow 
suppression, drug resistance and most notably, cardiotoxicity7,8. Stemming from a lack of 
selectivity toward cancer cells, these limitations could be overcome by the development of 
more advanced doxorubicin formulations9. This can be accomplished through formulation 
of the drug in nanoparticles. Nanoparticle formulations could provide a more controlled 
release of the drug load, and hence reduce peak levels or, could in ideal cases also promote 
increase drug deposition in tumor tissue by virtue of the enhanced permeability and 
retention (EPR) effect6,10–12. However, the relevance of the EPR effect for passive targeting 
of a broad range of tumors in human patients is currently under debate13. Currently two 
nanoparticulate liposomal doxorubicin formulations have been commercialized: 
Doxil/Caelyx (PEGylated) and Myocet (non-PEGylated)14,15.  These formulations are based 
on physical drug entrapment, which entails the risk of systemic release upon intravenous 
administration16. This risk can be mitigated through chemical conjugation to nanocarriers 
such as responsive polymeric nanoparticles, which gives access to a more selective drug 
release17–19.  
In contrast to physical formulation of a drug through hydrophobic interaction (e.g. in the 
core of amphiphiles) or inclusion (e.g. in the hollow void of liposomes), chemical 
conjugation is a much more robust strategy as it avoids disassembly of the carrier itself or 
the carrier-drug complex in response to dilution and interaction with serum proteins upon 
entry into blood circulation16,20. In this regard, antibody-drug conjugates are a successful 
example of how potent cytotoxic drugs can be more selectively delivered to tumor cells 
that overexpress a specific surface marker21. Besides that, many other systems based on 
polymeric/nanoparticles drug conjugates without a small or macromolecular targeting 
ligand are currently under (pre)clinical development10,22. A key feature in successful 
macromolecular design of polymer-drug conjugates is to insert a degradable linker 
between the drug molecule and the polymer backbone, which allows for gradual drug 
release (typically using hydrolysis of ester linkages) or to release the drug in response to 
specific stimuli in tumor tissue, or in endosomes upon cellular uptake9. For the latter 
purpose, cathepsin-cleavable peptides, acid-cleavable linkers such as hydrazones, ketals, 
substituted esters and reduction/disulfide exchange-sensitive disulfides and self-
immolative linkers derived thereof have been explored23–34. Akin to many of these 
strategies are challenging procedures required to synthesize complex macromolecular 
structures composed of drug, linker and polymer, and subsequent assembly into 3D 
structures. 
In this study, we present a straightforward approach based on polymeric activated ester 
scaffolds for the synthesis of polymer- and nanoparticle-doxorubicin conjugates using acid 
sensitive hydrazone linkages35. In contrast to previous reports using acetoxime acrylate36 
as precursor for the synthesis of polymeric hydrazones, the use of pentafluorophenyl (PFP) 
base activated ester scaffolds allows to perform nanoparticle assembly of block copolymers 
based on solvophobic interaction of the poly(pentafluorophenyl acrylate) blocks, hence 
highlighting the versatile nature of PFP-ester chemistry for the design of complex 
macromolecular architectures. 
Hydrazones exhibit strongly accelerated hydrolysis at mildly acidic pH and are therefore 
well suited for both endosomal and intra-tumoral drug release3,37. A requisite for the 
formation of a hydrazone bond is the presence of a carbonyl or hydrazide in the drug 
molecule and the corresponding counterpart (i.e. hydrazide or carbonyl) on the polymer 
backbone. A well-known example of a hydrazone-based polymer drug conjugate is 
doxorubicin-poly(N-hydroxypropylmethacrylamide) which has reached phase I/II clinical 
testing38. Doxorubicin-polymer conjugates are mostly obtained through copolymerization 
followed by several post-modification reactions. The resulting structures contain both 
hydrophilic repeating units to confer water-solubility and hydrazide moieties for drug 
conjugation. For more advanced structures, additional reactive moieties can be included 
as needed e.g. crosslinking or labeling with tracer molecules39. 
 Figure 1. Schematic representation of NanogelDOX. (A) Block copolymers composed of 
poly(pentafluorophenylacrylate) as hydrophobic block are self-assembled by solvophobic interaction 
into micellar nanoparticles in DMSO. The later solvent allows for subsequent core-modification of the 
nanoparticles without competing hydrolysis of the activated ester moieties, opposed to when self-
assembly would be performed in aqueous medium. (B) For core-modification, cross-linking is 
induced by bisamines that form inter- and intra-chain amide bonds. (C) Remaining 
pentafluorophenyl esters are transformed into hdyrazides and hydrophilic inert repeating units by 
reaction with hydrazine and aminoethanol. (D) After purification to remove unreacted species and 
by-products, doxorubicin is conjugated via its carbonyl moiety to the hydrazide moieties in the 
nanogel core by hydrazone-bond formation. (E) Doxorubicin is released from the nanogels by pH-
triggered hydrolysis of the hydrazone bond between the polymer backbone and doxorubicin. 
 
Our approach, depicted in Figure 1, is based on amphiphilic block copolymers consisting 
of a hydrophobic activated ester poly(pentafluorophenyl acrylate)40 block and a hydrophilic 
poly(N,N-dimethylacrylamide) block. These block copolymers self-assemble into 
nanoparticles in protic apolar solvents that can be cross-linked with bisamines41–44. We 
demonstrate that the activated esters can very efficiently be converted into hydrazides by 
treatment with hydrazine. After crosslinking, the latter allow for chemical conjugation of 
doxorubicin via an acid-labile hydrazone bound, yielding stable doxorubicin-loaded 
nanogels. We demonstrate cellular uptake of doxorubicin-loaded nanoparticles in vitro and 
with a minor decrease in cytotoxic activity relative to soluble doxorubicin. In vivo 
experiments in zebrafish embryos, a transparent vertebrate system that allows for 
straightforward high resolution whole animal fluorescence imaging of nanoparticle fate45,46, 
demonstrate a dramatic reduction in systemic toxicity relative to the free drug. In zebrafish 
model45 xenografted with tumor cells, we  show that the reduced drug toxicity upon 
nanoparticle encapsulation is accompanied by the selective accumulation of the 
nanoparticles in tumor tissue and a decrease in tumor growth. 
 
EXPERIMENTAL 
Materials 
All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. 
Pentafluorophenyl acrylate (PFP) and 2-(butylthiocarbonothioylthio)propanoic acid 
(PABTC) were synthesised as previously reported44,47. Deuterated solvents for NMR 
measurements were purchased from Deutero GMBH.  Spectra/Por 6 dialysis tubing with a 
MWCO of 3.5 kDa were ordered from Spectrum Labs. Doxorubicin was obtained from 
Lancrix. Cyanine5 amine was purchased from Lumiprobe. Dulbecco’s phosphate buffered 
saline (PBS), Dulbecco’s modified Eagle Medium (DMEM), Fetal bovine serum (FBS), L-
glutamine, penicillin, streptomycin, Hoechst and Alexa Fluor 647 phalloidin were purchased 
from Invitrogen. SKOV-3 and B16 cells were supplied by ATCC.  
Instrumentation 
1H- and 19F-NMR spectra were recorded on a Bruker FT NMR spectrometer at 300 or 500 
MHz.  
Dynamic light scattering (DLS) measurements were performed on Zetasizer Nano S 
(Malvern Instruments Ltd) equipped with a HeNe laser (λ=633 nm) and detection at a 
scattering angle of 173°. UV/Vis measurements were performed on a UV-1650PC 
(Shimadzu) and an Epoch 2 microplate reader (BioTek). 
Fluorospectrometry measurements were carried out on an EnVision Multilabel plate reader 
from Perkin Elmer. 
GPC was used for the determination of molecular weights and molecular weight distributions 
of polymers derived from RAFT polymerization performed on a Waters Instrument with an 
RI detector (2414 Waters), equipped with a Polymer Standards Services GPC precolumn 
(PSS SDV analytical 5 μ 8,0 x 50 mm) and three Polymer Standards Services GPC serial 
columns (PSS SDV analytical 1000 Å, 5 μ 8,0 x 300 mm, PSS SDV analytical 100000 Å, 5 
μ 8,0 x 300 mm, PSS SDV analytical 1000000 Å, 5 μ 8,0 x 300 mm) at 35 °C. Polystyrene 
standards were used for calibration. Chloroform stabilized with ethanol was used as eluent 
at a flow rate of 1 mL·min−1. Samples were injected using a Waters 717plus auto sampler. 
Synthesis of pDMA 
A dry Schlenk tube was filled with DMA (496 mg, 5.0 mmol), PABTC (24 mg, 0.1 mmol) 
and AIBN (1.6 mg, 0.010 mmol). Anhydrous dioxane was added to reach a total volume 
of 5 mL, dissolving all components. This solution was subjected to 5 freeze-pump-thaw 
cycles before initiating polymerization at 80°C for 3 hours under vacuum and continuous 
stirring. Monomer conversion was determined using 1H-NMR. The polymer was purified by 
triple precipitation in a 1:1 hexane:diethyl ether mixture. The obtained yellow powder was 
dried under high vacuum (495 mg, 0.099 mmol).  
Synthesis of pDMA-b-pPFPA  
A dry Schlenk tube was filled with PFPA (714 mg, 3.0 mmol), pDMA (333 mg, 0.067 mmol) 
and AIBN (2.2 mg, 0.013 mmol). Anhydrous dioxane was added to reach a total volume 
of 3 mL, dissolving all components. This solution was subjected to 5 freeze-pump-thaw 
cycles before initiating polymerization at 80°C for 3 hours under vacuum and continuous 
stirring. Monomer conversion was determined using 19F-NMR. The polymer was purified by 
triple precipitation in ice-cold hexane. The obtained slightly yellow powder was dried under 
high vacuum (877 mg, 0.067 mmol). 
Nanogel assembly 
Crosslinking 
800 mg pDMA-b-pPFPA (2.1 mmol reactive esters, 1.0 eq.) was divided equally over 2 dry 
round bottom flasks, equipped with a stir bar followed by the addition of 40 mL anhydrous 
DMSO under a nitrogen atmosphere. Ultrasonication (3 hours at room temperature) was 
applied to dissolve the polymer and allow micelle formation by solvophobic interaction 
between the pPFPA polymer blocks. In case of fluorescent labelling, 0.0050 eq. cyanine5-
amine (5.1 µmol, 3.4 mg) and 0.030 eq. TEA (31 µmol) were added to 1 of the flasks and 
the solution was incubated at 40°C for 3 days (NanogelCy5). After 3 days, 0.25 eq. 
(ethylenedioxy)bis(ethylamine) (0.26 mmol) and 5.0 eq. TEA (5.2 mmol) were added to 
each dispersion and the mixtures were stirred for 16 hours at 50°C to achieve crosslinking.  
Incorporation of hydrazides  
After crosslinking, an excess of 2.5 eq. ethanolamine (2.6 mmol) and 2.5 eq. hydrazine 
(2.6 mmol) was added to the crosslinked nanoparticle solution to ensure complete removal 
of all reactive PFP groups in presence of 15 eq. TEA (16 mmol).  
The reaction mixture was incubated at 50°C for another 20 hours before purification by 
dialysis. Dialysis was conducted using a dialysis membrane with a molecular weight cut-
off of 3.5 kDa in a 1:1 methanol:water mixture for three days, while gradually shifting the 
dialysis medium towards pure  water. After dialysis, the nanogels were freeze-dried and 
redispersed in PBS to be analyzed by DLS.  
Doxorubicin conjugation (NanogelDOX). 
Nanogels and 0.5 eq. doxorubicin for each hydrazide group were dissolved in anhydrous 
methanol at a doxorubicin concentration of 3.3 mM. Acetic acid (11 eq.) was added to aid 
the conjugation reaction48. This mixture was reacted overnight in the dark at room 
temperature, before being transferred to a dialysis membrane and dialyzed against 1L of 
a 0.05% ammonia buffer (pH 9.1). After 3 days of dialysis, the mixture was lyophilized.  
Doxorubicin content determination 
The amount of doxorubicin conjugated to the polymers was determined by UV-vis 
spectrometry at a wavelength of 481 nm. A standard concentration curve with doxorubicin 
concentrations between 0.005 and 0.1 mg/mL was prepared in PBS. Samples of each 
doxorubicin containing nanoparticle were prepared in PBS and analyzed at 481 nm. The 
doxorubicin content of the different formulations was determined by comparing it to the 
values of the standard curve. 
Doxorubicin release 
A nanoparticle formulation containing 0.5 mg/mL NanogelDOX was prepared in PBS. The 
formulation (1.5 mL) was transferred into a dialysis membrane and dialyzed against 40 mL 
PBS or 50 mM acetate buffer pH 5. The dialysis tubes were incubated at 37°C and samples 
were collected by withdrawing 2 mL of the dialysis medium and replacing it with 2 mL of 
fresh medium. Samples were taken at 1, 2, 4, 6, 24, 48, 72, 96, 120 and 168 hours. The 
experiment was done in triplicate. The doxorubicin content of each sample was determined 
by fluorescence spectrometry at an excitation wavelength of 480 nm and an emission 
wavelength of 590 nm. Calibration curves in both buffers are shown in Figure S9 in 
Supporting Information. 
In vitro cell experiments 
Cell culture 
SKOV-3 human ovarian cancer cells and B16 murine melanoma cells were cultured in 
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 µg/mL streptomycin and 50 
units/mL penicillin. Cells were incubated in a controlled, sterile environment at 37°C, 95% 
relative humidity and 5% CO2. 
Cytotoxicity 
In vitro cytotoxicity was determined by MTT assay. SKOV-3 and B16 cells were seeded in 
96-well plates (10 000 cells per well, suspended in 200 µL cell medium) and incubated 
overnight. The next day, 50 µL formulation, DMSO (positive control = 0% viability) or PBS 
(negative control = 100% viability) was added to the wells, followed by a 72h incubation 
period. Formulations of soluble doxorubicin and NanogelDOX in PBS were prepared with 
doxorubicin concentrations between 500 µg/mL and 2.5 ng/mL. After 72 hours, the 
medium was aspirated and the cells were washed with 200 µL PBS. After aspiration, 100 
µL MTT working solution was added to each well and the cells were incubated for 2.5 hours. 
The MTT working solution was prepared by dissolving 100 mg thiazolyl blue tetrazolium 
bromide in 20 mL PBS, followed by membrane filtration (0.22 µm) and 5-fold dilution in 
cell culture medium. After 2.5 hours, the MTT working solution was aspirated and the 
formed formazan crystals were dissolved in 50 µL DMSO. The absorbance of each well was 
measured at 590 nm. The absorbance of the blank wells was used as a positive control and 
thus subtracted from all values.  
Cellular uptake and intracellular fate  
SKOV-3 cells were seeded in confocal dishes (5 000 cells per dish, suspended in 200 µL 
cell medium) and incubated overnight. The next day, 300 µL sample was added to each 
well. Samples of soluble doxorubicin and NanogelDOX in PBS were prepared with 
doxorubicin concentrations of 5 µg/mL. The dishes were incubated for 48h before fixation, 
using 4% PFA. All samples were washed with PBS and stained with Hoechst and Alexa Fluor 
phalloidin 488. This staining solution was prepared by adding 20 µL of 1 mg/mL Hoechst 
stock solution and 50 µL of a 200 units/mL Alexa Fluor phalloidin 488 stock solution to 2 
mL PBS.  Following another washing step, the cells were imaged using a Leica DMI6000B  
microscope with a 63X, 1.40 NA objective, attached to an Andor DSD2 confocal scanner. 
In vivo experiments in zebrafish embryos  
Systemic toxicity testing 
Samples of free doxorubicin and NanogelDOX were diluted in a deionized water solution 
containing a 2% polyvinylpyrrolidone (PVP) in order to reach a doxorubicin concentrations 
of 2 mg/mL or 4 mg/mL. For each condition 20-30 zebrafish embryos were injected with 
sample volumes between 0.5 and 20 nL, 3 days after fertilization. The diluting medium 
alone was used as control. Over the next 6 days, the fish were incubated at 32°C and 
assessed for their survival in each treatment condition.  
Tumor accumulation 
B16 mouse melanoma cells expressing RFP or GFP were injected in zebrafish embryos 
zebrafish embryos at 2 days post fertilization and incubated at 32°C. Five days after the 
xenotransplant we intravenously injected 5 nL of a 4 mg/mL solution of  NanogelCy5. The 
tumor region in the zebrafish was then imaged at 1 day post injection using the confocal 
A 
B
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microscope Zeiss LSM 880 with Fast AiryScan using a Leica LD LCI 25X/0.8 objective with 
oil immersion.  
Therapeutic evaluation 
At two days post fertilization, B16 mouse melanoma cells expressing RFP were injected 
into the neural tube of zebrafish embryos and subsequently incubated at 32°C. 3 days post  
fertilization, the fish were injected with free doxorubicin 4 mg/kg or nanogel-conjugated 
doxorubicin at 40 mg/kg. As control groups we injected zebrafish larvae with an equivalent 
concentration of doxorubicin-free nanogels or with the diluting medium alone. Five days 
post injection, the tumors were imaged using a Leica DFC365FX stereo microscope with a 
1.0x plan apo lens. In order to assess the effect of the treatment on tumor growth, the 
florescence of the cancer cells in each group were compared using the software Image J. 
Zebrafish larvae dying because of toxicity were removed and not included in the final 
graph. 
 
RESULTS AND DISCUSSION 
Amphiphilic block copolymers composed of N,N-dimethylacrylamide (DMA) and 
pentafluorophenylacrylate (PFPA) were synthesized by RAFT polymerization using 2-
(butylthiocarbonothioylthio)propionic acid (PABTC) as chain transfer agent (CTA) and AIBN 
as radical initiator (Scheme 1). The hydrophilic pDMA block was first synthesized with a 
targeted degree of polymerization (DP) of 50. The conversion of DMA was determined by 
1H-NMR to be 96%, yielding p(DMA48), which subsequently served as macroCTA for the 
next block. For the latter, PFPA was RAFT polymerized targeting a DP of 45. 19F-NMR 
revealed a monomer conversion of 74%, resulting in a p(DMA48-b-PFPA34) polymer. The 
size distribution of the (block) copolymers were analyzed by size exclusion chromatography 
(SEC) and the polymer properties are shown in Table 1. 
Scheme 1. Synthesis of poly(DMAn) macroCTA and p(DMA)-b-p(PFPA) via RAFT polymerization. 
 
 
A 
B
A 
Scheme 2. Crosslinking (green) of p(DMA)-b-p(PFPA) (A) and substitution of remaining 
active esters with hydrazine and ethanolamine (red) (B). 
 
 
Scheme 3. Conjugation of doxorubicin (orange) to hydrazide groups, forming a 
hydrazone bond. 
  
Table 1. Compositional data of the synthesized polymers. 
 [monomer]/[CTA] Conversion (%) a DP 
(NMR) 
MW (kDa) A MW (kDa) B  Ð B 
p(DMA) 50 96 48 5.0 3.9 1.13 
p(DMA)-b-poly(PFPA) 45 74 34 13 6.3 1.51 
ACalculated using 1H NMR. BAnalyzed by SEC 
 
Table 2. Z-average diameter and PDI during the synthesis of the nanogels as measured by DLS. 
 Solvent Z-average (±SD) PDI (±SD) ζ-potential 
(mV) 
before crosslinking DMSO 91 (±9) 0.620 (±0.177) / 
after crosslinking DMSO 74 (±1) 0.458 (±0.021) / 
after freeze drying PBS 85 (±6) 0.605 (±0.111) -7.35 (±6.63) 
after doxorubicin conjugation PBS 75 (±0.4) 0.338 (±0.007) -8.37 (±8.08) 
 
 The block copolymer was dissolved in DMSO and dynamic light scattering (DLS) revealed 
the formation of nanoparticles with a mean hydrodynamic diameter of 91 nm. Although 
hydrolysis of the PFP esters cannot be fully excluded, this is minimal when using anhydrous 
solvents. Moreover, PFP-esters are known to be resilient towards hydrolysis while showing 
high reactivity towards primary amines40. The nanoparticles were then subjected to a core-
crosslinking step by the addition of 2.2’-(ethylenedioxy)bis(ethylamine) (Scheme 2), 
resulting in the formation of amide bonds between the PFPA repeating units. In this 
reaction, 0.25 equivalents of 2.2’-(ethylenedioxy)bis(ethylamine) relative to the number 
of reactive esters were added. Crosslinking is intended to ´lock´49 the nanoparticle state, 
followed by reacting the remaining PFP-esters with a 5 eq. excess of a 50:50 equimolar 
mixture of hydrazine and 2-ethanolamine. A small hydrophilic amine such as 2-
ethanolamine should render the core of the nanoparticles sufficiently hydrophilic and, 
hence, promote full hydration upon transfer to aqueous medium by dialysis at the final 
step of the formulation process. Whereas, modification with a small hydrophobic amine 
would yield amphiphilic structures that will self-assemble into micellar nanoparticles in 
aqueous medium, it is important to note that non-crosslinked block copolymer micelles are 
commonly prone to disassembly upon dilution in complex physiological media49. Moreover, 
doxorubicin is insufficiently hydrophobic to drive assembly into micelles with high 
physiological stability. In the present study, for a proof-of-concept, we focused only on a 
non-degradable crosslinker. However, the synthesis of degradable nanogels can be 
achieved using bisamine crosslinkers containing a degradable bond such as a disulfide or 
a ketal42,43,50,51. For the synthesis of fluorescently labelled nanogels (NanogelCy5), 2% of 
the reactive esters on the polymer were substituted with cyanine5-amine prior to 
crosslinking. We chose cyanine5 as a labelling agent because its fluorescence excitation 
and emission spectra do not, contrary to rhodamine and fluorescein, show overlap with the 
spectra of doxorubicin52. 
To address potential concerns regarding additional crosslinking upon reaction of the PFP-
esters with hydrazine and 2-aminoethanol53, a control experiment was performed in which 
bisamine-crosslinking was omitted and only the 5 eq. excess of hydrazine and 2-
ethanolamine (50:50) was added. After purification, the reaction product was measured 
by DLS, revealing a size distribution corresponding to unimers (Figure S8 in Supporting 
Information). Hence we concluded that neither hydrazine nor 2-aminoethanol induced 
additional crosslinking, which is in line with our previous findings42 on substitution of 
polymeric activated ester scaffolds with 2-aminoethanol. 
After dialysis to remove unreacted species and released pentafluorophenol, the hydrazide 
groups in the nanogel core were used for doxorubicin conjugation through the formation 
of an acid-labile hydrazine bond (Scheme 3; NanogelDOX). This linkage provides stable 
conjugation at neutral, physiological pH conditions, but shows accelerated hydrolysis at 
mildly acidic pH, as encountered in the tumor microenvironment and in endolysosomal 
vesicles (e.g. early endosomes have a pH around 6.2; lysosomes around 5 or below54). 
Towards this goal, we prepared doxorubicin-conjugated nanogels with doxorubicin 
equivalents corresponding to half of the hydrazide groups on the nanogels added for 
conjugation. After dialysis against water, the final concentration of doxorubicin conjugated 
to the nanogels was determined by UV/Vis spectrometry to be 19 % (w/w). Determination 
of the doxorubicin content was done by UV/Vis spectrometry, and not fluorimetry, to avoid 
interference with fluorescence quenching of the doxorubicin inside the nanogel core.  
To assess the suitability of the hydrazone bond between the polymer backbone and the 
doxorubicin for accelerated drug release at slightly acidic conditions, we loaded the 
NanogelDOX in dialysis tubes and placed these in either neutral or slightly acidic medium 
at 37°C. The amount of doxorubicin released in the medium outside the dialysis bags at 
either pH was quantified by fluorimetry over the next 6 days. Detection via fluorimetry was 
prefered over UV/Vis spectrometry due to its lower limit of detection, necessary to quantify 
the low concentrations in this experiment. Calibration curves at both pH values are shown 
in Figure S9 in Supporting Information. Figure 2 shows that doxorubicin release occurred 
at pH 5, whereas at the physiological pH of 7.4, doxorubicin release was significantly less, 
even after 6 days. These results demonstrate the stability of the hydrazone bound at 
neutral physiological conditions, while confirming its suitability for drug release at acidic 
conditions. When injected into the blood circulation, doxorubicin is expected to remain 
predominantly conjugated to the nanogels and become released much faster upon entering 
the tumor environment or upon endosomal uptake by cancer cells due to accelerated 
hydrazone cleavage under acidic conditions54.  
0 50 100 150
0
10
20
30
40
pH 7
pH 5
Time (h)
C
u
m
u
la
ti
v
e
 d
ru
g
 r
e
le
a
s
e
 (
%
)
 
Figure 2. Cumulative release profile doxorubicin from NanogelDOX  formulation at physiological (red) 
and endo-lysosomal acidic (blue) pH. 
 
Cellular uptake of NanogelDOX was first assessed in vitro on SKOV-3 human ovarian cancer 
cells via confocal microscopy, taking advantage of the intrinsic fluorescence of doxorubicin 
(Figure 3). Whereas doxorubicin in soluble form exhibited accumulation  predominantly in 
the cell nucleus, NanogelDOX showed a much more punctuated pattern, with only part of 
the fluorescence signal being localized to the nucleus. Free doxorubicin can permeate 
across cell membranes and hence spontaneously accumulate in the cell nucleus, via its 
binding to DNA. By contrast, NanogelDOX needs to enter the cell by endocytosis, ending 
up in intracellular endosomal vesicles, hence the punctuated pattern. From these 
endosomes doxorubicin is gradually released by pH-accelerated cleavage of the hydrazone 
bonds, allowing to diffuse through the endosomal membrane and accumulate in the cell 
nucleus.  
 
Figure 3. Confocal images of SKOV-3 cells incubated with soluble doxorubicin (A) and NanogelDOX 
(B) for 48 hours. Cell nuclei and membranes are depicted in blue and green respectively. Doxorubicin 
is visualized in red. 
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Figure 4. In vitro cytotoxicity evaluation on B16 (triangle) and SKOV-3 (circle) cells after 72 hours 
of incubation with different doses of soluble doxorubicin (blue) and NanogelDOX (red).  
 Figure 5. In vivo evaluation in zebrafish embryo. (A,C) NanogelCy5 accumulation into 
tumors (A) Fluorescence microscopy (A1) of a representative B16 tumor-bearing zebrafish 
embryo and (A2) corresponding confocal microscopy image (3D images calculated from a 
z-stack) of the tumor region. B16 melanoma cells are shown in red, zebrafish vascular 
endothelium in green and NanogelCy5 in violet. (B) Toxicity evaluation: Survival analysis 
of zebrafish embryo injected with different concentrations of doxorubicin either in free form 
or NanogelDOX. n=20, Student´s t-test ****: p<0,0001 (C): Quantification of the 
fluorescent signal of NanogelCy5 in the area of the tumor or in an equivalent region of the 
neural tube without cancer cells. Student´s t test , n=30, ****: p<0,0001 (D) Therapeutic 
evaluation: Quantification of the fluorescent signal of cancer cells in xenotransplanted 
zebrafish embryo after treatment with doxorubicin as a free drug or NanogelDOX. 
Doxorubicin-free nanogels or diluting medium alone were used as controls. n(no 
treatment)= 20, n(blank nanogels)= 20, n(DOX)>38, n(nanogelDOX)>20. One way Anova, 
*: p<0,02, **: p<0,005, ***: p<0,0005. 
 
Next, we investigated the cytotoxic activity of nanogel-conjugated doxorubicin by MTT 
assay in SKOV-3 and B16 mouse melanoma cells. In both cases, nanogel-conjugation 
resulted in a decrease in cytotoxic activity (Figure 4). This is a known phenomenon, 
whereas doxorubicin in free form is rapidly bioavailable, when conjugated to nanogels it 
has first to be released at low pH, a process that can explain the reduction in toxicity55,56. 
 
As a final part of this work we aimed to perform an in vivo screening of the therapeutic 
potential of NanogelDOX. For this purpose we made use of a zebrafish embryo ´pre-
murine´ in vivo model. Zebrafish embryos are fully transparent which allows for whole 
animal imaging using standard fluorescence and microscopy equipment. This allows for 
straightforward investigation of the pharmacokinetics of fluorescently labelled structures 
at sub-cellular resolution, especially in combination with transgenic zebrafish with 
fluorescent tissues, such as eGFP-expressing vasculature, as used in our present study.  
We first assessed whether the reduction in toxicity observed in cultured cells could also be 
detected in zebrafish embryo. For this, we intravenously (i.e. in the caudal vein) injected 
two days old embryos with different concentrations of doxorubicin either in free form or 
conjugated to nanogels and monitored the embryos survival in the following days. 
Doxorubicin alone was found to be toxic even at 1 mg/kg (1 ng doxorubicin) while 
NanogelDOX dramatically reduced its negative effects as a 40 mg/kg (40 ng doxorubicin) 
dose injected animals was found to be undistinguishable from mock injected controls 
(Figure 5B).  
We next used a zebrafish xenograft tumor model to investigate tumor accumulation and 
tumor growth reduction in response to NanogelDOX treatment. In these experiments, we 
implanted B16 mouse melanoma cells, expressing RFP (red fluorescent protein) into the 
neural tube of zebrafish embryo. As the adaptive immune system is inactive during the 
first month of development, cells form other species can be xenografted and allowed to 
proliferate without facing rejection from the host. We focused on the localization of 
fluorescent nanogels after bloodstream injection in respect to zebrafish larvae 
xenotransplanted in the region of the neural tube with B16 cancer cells. Interestingly, the 
tumor region shows extensive neovascularization, evidenced by an irregular structure 
compared to the rectangular vasculature of healthy zebrafish tissue, interpenetrating the 
red fluorescent tumor mass. This feature highlights the potential of this zebrafish xenograft 
model for studying the behavior of drug delivery systems in a physiological context and for 
investigating EPR-like tumor accumulation. Fluorescence imaging performed one day after 
nanoparticle injection revealed a significant increase in NanogelCy5 accumulation in the 
tumor area when compared to an equivalent region of the neural tube (Figure 5A,C). 
Finally we tested the ability of NanogelDOX to inhibit the growth of xenografted B16 cells 
in zebrafish embryo. For this we first injected the cancer cells in the neural tube at two 
days post fertilization. The day after we injected into the caudal vein either 40 mg/kg (40 
ng) of NanogelDOX or the highest dose of free drug that had moderate toxicity, 4 mg/kg 
(4 ng). As controls we included zebrafish larvae injected with doxorubicin-free nanogels or 
with the diluting medium. While free doxorubicin did not exhibit any effect, NanogelDOX 
were able to reduce the B16 fluorescence signal by half and therefore significantly reduce 
tumor growth (Figure 5D).  
 
Conclusion 
We demonstrated a straightforward route, based on activated esters, for the synthesis of 
core-crosslinked nanogels that contain hydrazide moieties in their core that can be used 
for doxorubicin conjugation. The resulting NanogelDOX provided accelerated drug release 
under acidic conditions. NanogelDOX could be endocytosed by cancer cells in vitro and 
thereby killing them, although with decreased activity relative to doxorubicin in soluble 
form. In vivo screening experiments in tumor-bearing zebrafish embryo indicated a 
dramatic reduction in systemic toxicity, but enhanced tumor accumulation and tumor 
growth reduction. Our findings also highlight the  power of the zebrafish embryo tumor 
model for rapid screening of drug nanocarriers in a physiological context. In our future 
endeavors, we will further elaborate on PFP activated esters as scaffolds for drug 
conjugation and focus on the development of systems that contain a degradable crosslinker 
and include of cancer cell receptor targeting ligands at the hydrophilic polymer chain ends.  
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